Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has issued an announcement.
On August 1, 2025, Smith & Nephew plc announced its total issued share capital as of July 31, 2025, which comprises 877,710,150 ordinary shares, including 1,748,679 held in treasury. This announcement is crucial for shareholders as it determines the denominator for notifying changes in their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (SNN) stock is a Hold with a $27.71 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats is well-positioned due to strong financial performance and positive earnings call sentiment, highlighting growth and strategic execution. The technical analysis indicates a strong upward trend, although overbought conditions may pose short-term risks. The high P/E ratio suggests potential overvaluation, but the dividend yield adds some appeal for income-focused investors.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a leading company in the medical technology industry, specializing in advanced wound management, orthopedics, and sports medicine. The company focuses on providing innovative solutions to improve patient outcomes and operates on a global scale.
Average Trading Volume: 856,004
Technical Sentiment Signal: Buy
Current Market Cap: $13.42B
See more insights into SNN stock on TipRanks’ Stock Analysis page.